Evaluation and Management of Testicular Cancer After Late Relapse
Oncology (Williston Park). 2024 Apr 11;38(4):142-146. doi: 10.46883/2024.25921018.ABSTRACTA 41-year-old man presented to his primary care physician with a 1-month history of left neck adenopathy in the context of a history of nonseminomatous germ cell tumors (NSGCTs). In 2011, the patient was treated for stage IB (T2N0M0S0) right-sided NSGCTs of the testis, which were 95% embryonal and 5% yolk sac tumors. He underwent a right radical orchiectomy and was followed until 2022 without recurrence. In the work-up for his adenopathy, laboratory results for human chorionic gonadotropin, lactate dehydrogenase, and α-fetoprotein we...
Source: Oncology (Williston Park, N.Y.) - April 25, 2024 Category: Cancer & Oncology Authors: Joanna L Langner Frederick Millard Vera Vavinskaya Haiyan Zhang Nuphat Yodkhunnatham Aditya Bagrodia Source Type: research
Long-term quality of life of testicular cancer survivors differs according to applied adjuvant treatment and tumour type
ConclusionsThe applied adjuvant treatment and the tumour entity had a significant impact on the long-term QoL of TC survivors, even more than 25 years after the completion of therapy. Both RT and CT had a negative impact compared to survivors treated with RPLND, except for sexual concerns. NSGCT survivors had a lower impairment of QoL compared to seminoma survivors, except in terms of sexual concerns.Implications for Cancer SurvivorsImplications for cancer survivors are to raise awareness of aspects of long-term and late effects on QoL in TC survivors; offer supportive care, such as psycho-oncological support or lifestyl...
Source: Journal of Cancer Survivorship - April 24, 2024 Category: Cancer & Oncology Source Type: research
Antibody Drug Conjugates in Urological Cancers: A Review of the Current Landscape
AbstractPurpose of ReviewOur review delves into the progress across urological malignancies and discusses ongoing challenges and future directions in antibody –drug conjugate (ADC) development, emphasising their transformative potential in cancer care.Recent FindingsADCs have advanced from hematologic to solid tumours, notably in breast cancer, and are now pivotal in metastatic urological cancers as both monotherapies and in combination regimens, underscored by the FDA ’s approval of enfortumab vedotin and sacituzumab govitecan for metastatic urothelial cancer. Progress in metastatic prostate cancer, particularly with ...
Source: Current Oncology Reports - April 23, 2024 Category: Cancer & Oncology Source Type: research
Contemporary Role of Radiation Therapy in Testicular Cancer
Testicular cancer is a rare but curable male malignancy. Seminoma represents the majority of germ cell tumors and is considered radiation sensitive. Radiation treatment plays a role in adjuvant therapy after orchiectomy of stage I, IIA, and IIB seminomas. Radiation dose de-escalation has been effective in preventing tumor recurrences while also limiting acute and long-term toxicities. However, long-term risks, including the prevailing concern of secondary malignancy risk, between adjuvant radiation and chemotherapy play a role in recommendations. Ongoing work continues to be performed to reduce radiation field and dose in ...
Source: Urologic Clinics of North America - April 21, 2024 Category: Urology & Nephrology Authors: Jay C. Shiao, Xinglei Shen Source Type: research
Utilization of sperm cryopreservation in patients with testicular cancer
ConclusionsAge and education seem to impact the choice of undergoing paid sperm cryopreservation. Urologists should inform testicular cancer patients about costs and coverage. Importantly, the occurrence of unmet desires for parenthood is minimal among those who forego cryopreservation. (Source: Journal of Cancer Research and Clinical Oncology)
Source: Journal of Cancer Research and Clinical Oncology - April 17, 2024 Category: Cancer & Oncology Source Type: research
Cancers, Vol. 16, Pages 1520: Identification and In Vivo Validation of Unique Anti-Oncogenic Mechanisms Involving Protein Kinase Signaling and Autophagy Mediated by the Investigational Agent PV-10
Narendran
PV-10 is a 10% formulation of rose bengal sodium that has potent immunotherapeutic and anti-cancer activity against various tumors, including metastatic melanoma and refractory neuroblastoma. Currently, PV-10 is undergoing clinical testing for refractory metastatic neuroendocrine cancer and melanomas. However, preclinical investigation of PV-10 activity and its mechanisms against phenotypically and molecularly diverse adult solid tumors had not been conducted. In a panel of human cell lines derived from breast, colorectal, head and neck, and testicular cancers, we demonstrated that PV-10 induces cytotoxicity ...
Source: Cancers - April 16, 2024 Category: Cancer & Oncology Authors: Son Tran Patrick Sipila Satbir Thakur Chunfen Zhang Aru Narendran Tags: Article Source Type: research
Testicular Cancer Survivorship and Fertility Preservation
Testicular cancer disproportionally affects men of reproductive age making fertility an important aspect of testicular cancer survivorship. Men with testicular cancer have more semen parameter abnormalities and a higher incidence of infertility compared to the general population. All treatment options for testicular cancer negatively affect fertility with recovery rates varying by treatment. For these reasons, clinicians should offer sperm cryopreservation, ideally before orchiectomy to maximize the possibility of biologic paternity, if desired. Several innovations have positively impacted this space including direct-to-co...
Source: Urologic Clinics of North America - April 16, 2024 Category: Urology & Nephrology Authors: Aaron Tverye, Ajay Nangia, Richard J. Fantus Source Type: research
Familial syndromes associated with testicular and paratesticular neoplasms: a comprehensive review
AbstractA syndromic association between a subset of testicular/paratesticular neoplasms is well established. Such examples include Carney complex and large cell calcifying Sertoli cell tumor, Peutz-Jeghers syndrome and intratubular large cell hyalinizing Sertoli cell neoplasia, and VHL syndrome and clear cell papillary cystadenoma of the epididymis.However, recent studies proposed potential novel links between some testicular and paratesticular neoplasms with certain tumor syndromes. While more studies are still needed to solidify these associations, recent research suggests that a subset of Leydig cell tumors may arise in...
Source: Virchows Archiv - April 15, 2024 Category: Pathology Source Type: research
Forthcoming Issues
Advances in Penile and Testicular Cancer (Source: Urologic Clinics of North America)
Source: Urologic Clinics of North America - April 11, 2024 Category: Urology & Nephrology Source Type: research
Update on the Management of Low-stage Seminoma
The contemporary paradigm of testicular cancer management is achieving high and durable cure rates while minimizing the burden of treatment given the potential long-term toxicities associated with radiation therapy and systemic therapies. The management of low-stage seminoma has seen significant changes in recent years. Nuances of surveillance strategies for stage I seminoma exist and continue to evolve. Emerging data show retroperitoneal lymph node dissection is a viable treatment option for selected patients with clinical stage IIA and IIB seminoma. (Source: Urologic Clinics of North America)
Source: Urologic Clinics of North America - April 9, 2024 Category: Urology & Nephrology Authors: Leilei Xia, Siamak Daneshmand Source Type: research
Restricted access and advanced disease in post-pandemic testicular cancer
CONCLUSIONS: There was a 16.8% rise in clinical stage III disease from the pre-pandemic to post-pandemic period. Our study failed to identify a statistically significant increase in metastatic testis cancer incidence upon lifting of pandemic restrictions. Further study is necessary to confirm suspicions that pandemic restrictions contributed to increased incidence of metastatic testis cancer.PMID:38587978 | DOI:10.5489/cuaj.8648 (Source: Canadian Urological Association Journal)
Source: Canadian Urological Association Journal - April 8, 2024 Category: Urology & Nephrology Authors: Mitchell Fagan W C Ian Janes Matthew Andrews David R Harvey Geoff M Warden Michael K Organ Paul Johnston Source Type: research
Restricted access and advanced disease in post-pandemic testicular cancer
CONCLUSIONS: There was a 16.8% rise in clinical stage III disease from the pre-pandemic to post-pandemic period. Our study failed to identify a statistically significant increase in metastatic testis cancer incidence upon lifting of pandemic restrictions. Further study is necessary to confirm suspicions that pandemic restrictions contributed to increased incidence of metastatic testis cancer.PMID:38587978 | DOI:10.5489/cuaj.8648 (Source: Canadian Urological Association Journal)
Source: Canadian Urological Association Journal - April 8, 2024 Category: Urology & Nephrology Authors: Mitchell Fagan W C Ian Janes Matthew Andrews David R Harvey Geoff M Warden Michael K Organ Paul Johnston Source Type: research
Restricted access and advanced disease in post-pandemic testicular cancer
CONCLUSIONS: There was a 16.8% rise in clinical stage III disease from the pre-pandemic to post-pandemic period. Our study failed to identify a statistically significant increase in metastatic testis cancer incidence upon lifting of pandemic restrictions. Further study is necessary to confirm suspicions that pandemic restrictions contributed to increased incidence of metastatic testis cancer.PMID:38587978 | DOI:10.5489/cuaj.8648 (Source: Canadian Urological Association Journal)
Source: Canadian Urological Association Journal - April 8, 2024 Category: Urology & Nephrology Authors: Mitchell Fagan W C Ian Janes Matthew Andrews David R Harvey Geoff M Warden Michael K Organ Paul Johnston Source Type: research
Restricted access and advanced disease in post-pandemic testicular cancer
CONCLUSIONS: There was a 16.8% rise in clinical stage III disease from the pre-pandemic to post-pandemic period. Our study failed to identify a statistically significant increase in metastatic testis cancer incidence upon lifting of pandemic restrictions. Further study is necessary to confirm suspicions that pandemic restrictions contributed to increased incidence of metastatic testis cancer.PMID:38587978 | DOI:10.5489/cuaj.8648 (Source: Canadian Urological Association Journal)
Source: Canadian Urological Association Journal - April 8, 2024 Category: Urology & Nephrology Authors: Mitchell Fagan W C Ian Janes Matthew Andrews David R Harvey Geoff M Warden Michael K Organ Paul Johnston Source Type: research
Restricted access and advanced disease in post-pandemic testicular cancer
CONCLUSIONS: There was a 16.8% rise in clinical stage III disease from the pre-pandemic to post-pandemic period. Our study failed to identify a statistically significant increase in metastatic testis cancer incidence upon lifting of pandemic restrictions. Further study is necessary to confirm suspicions that pandemic restrictions contributed to increased incidence of metastatic testis cancer.PMID:38587978 | DOI:10.5489/cuaj.8648 (Source: Canadian Urological Association Journal)
Source: Canadian Urological Association Journal - April 8, 2024 Category: Urology & Nephrology Authors: Mitchell Fagan W C Ian Janes Matthew Andrews David R Harvey Geoff M Warden Michael K Organ Paul Johnston Source Type: research
